Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO

Biopharmaceutical company Attovia Therapeutics said on Tuesday it was targeting a valuation of $731.5 ​million in its upsized initial public ‌offering, signaling strong demand for biopharma listings.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。